Aurobindo Pharma Limited announced its consolidated financial results for the quarter ended September 30, 2024. Net Profit for the period stood at Rs. 817 crore, vs. Rs. 752 crore in Q2FY24. Revenue from Operations increased by 8 per cent YoY to Rs 7,796 crore with growth across the businesses.US formulations (excluding Puerto Rico) revenue increased by 4.3 per cent to Rs. 3,530 crore. Europe formulations revenue increased by 19 per cent YoY to Rs. 2,105 crore. Growth markets revenue increased by 44 YoY to Rs. 812 crore.

Commenting on the company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: "We are pleased with the continued growth in revenues across our key business areas this quarter, reflecting the resilience of our diversified portfolio. While profitability saw a slight dip, primarily due to the transient nature of certain business activities, our underlying performance remains strong. With a solid foundation and ongoing operational improvements, we are confident of maintaining our growth trajectory and achieving our strategic objectives for the year."